- Home
- GS vs AZN Comparison
GS vs AZN Comparison
Compare GS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GS
- AZN
- Stock Information
- Founded
- GS 1869
- AZN 1992
- Country
- GS United States
- AZN United Kingdom
- Employees
- GS N/A
- AZN N/A
- Industry
- GS Investment Bankers/Brokers/Service
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- GS Finance
- AZN Health Care
- Exchange
- GS Nasdaq
- AZN Nasdaq
- Market Cap
- GS 182.7B
- AZN 212.2B
- IPO Year
- GS 1999
- AZN 1993
- Fundamental
- Price
- GS $626.00
- AZN $66.60
- Analyst Decision
- GS Buy
- AZN Buy
- Analyst Count
- GS 17
- AZN 9
- Target Price
- GS $589.19
- AZN $88.80
- AVG Volume (30 Days)
- GS 2.3M
- AZN 5.0M
- Earning Date
- GS 01-15-2025
- AZN 02-06-2025
- Dividend Yield
- GS 1.92%
- AZN 2.23%
- EPS Growth
- GS 77.30
- AZN 9.79
- EPS
- GS 40.54
- AZN 4.15
- Revenue
- GS $52,164,000,000.00
- AZN $51,206,000,000.00
- Revenue This Year
- GS $9.19
- AZN $18.56
- Revenue Next Year
- GS $4.86
- AZN $7.44
- P/E Ratio
- GS $15.44
- AZN $31.70
- Revenue Growth
- GS 15.34
- AZN 13.81
- 52 Week Low
- GS $372.07
- AZN $60.47
- 52 Week High
- GS $626.98
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- GS 69.44
- AZN 50.73
- Support Level
- GS $556.76
- AZN $64.22
- Resistance Level
- GS $593.65
- AZN $67.57
- Average True Range (ATR)
- GS 12.30
- AZN 0.85
- MACD
- GS 5.07
- AZN 0.12
- Stochastic Oscillator
- GS 98.60
- AZN 67.04
About GS Goldman Sachs Group Inc. (The)
Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.